Veloxis to put all behind 'improved Prograf'
This article was originally published in Scrip
Danish firm Veloxis Pharmaceuticals (formerly LifeCycle Pharma) is planning a restructuring of its operations to focus fully on the development and potential commercialisation of its lead product LCP-Tacro, a once-daily tablet version of tacrolimus, for the prevention of organ rejection. This involves a discontinuation of all other pipeline activities. The company also wants to build an in-house marketing and sales organisation in the US. "Our strategy is to commercialise ourselves in the US and to partner in all other territories," CEO William Polvino told Scrip. "We are in active dialogue with our potential partners and will announce deals as they occur."
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.